Affinage

PRMT6

Protein arginine N-methyltransferase 6 · UniProt Q96LA8

Length
375 aa
Mass
41.9 kDa
Annotated
2026-06-10
100 papers in source corpus 64 papers cited in narrative 64 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRMT6 is a nuclear type I protein arginine methyltransferase that catalyzes asymmetric dimethylation of arginine residues on histone and non-histone substrates to control transcription, cell cycle progression, mitosis, and metabolic state (PMID:11724789, PMID:18079182). Its defining chromatin activity is deposition of H3R2me2a, the major H3R2 mark in cells, which represses transcription by blocking WDR5/MLL-dependent H3K4 trimethylation at targets including Hox, Myc, p21/CDKN1A, p27, and Trp53 (PMID:18079182, PMID:22904064, PMID:22987071, PMID:22916108); at enhancers the same mark instead supports KMT2D recruitment and activating H3K4me1/H3K27ac, giving PRMT6 context-dependent dual roles during differentiation (PMID:30232013). PRMT6 also writes H2AR29me2a and is functionally redundant with CARM1 for H3R17me2a (PMID:21774791, PMID:33008887), and its H3R2me2a-coated chromosome arms recruit the Aurora B chromosomal passenger complex to drive mitotic H3S10 phosphorylation and chromosome condensation (PMID:32001712). Beyond chromatin, PRMT6 methylates a broad set of non-histone substrates—including PTEN at R159 to suppress PI3K-AKT signaling, CRAF at R100 to alter RAS/MEK-ERK output and glycolysis, FOXO3 to drive autophagy and muscle atrophy, RCC1 to activate RAN GTPase in mitosis, and huntingtin at R118 to support vesicular axonal transport—integrating it into growth, metabolic, and neuronal pathways (PMID:30886105, PMID:30332648, PMID:31469916, PMID:30653406, PMID:33539787, PMID:33852844). PRMT6 prefers RG motifs with basic or bulky flanking residues and operates through a rapid-equilibrium random kinetic mechanism, with crystal structures defining its asymmetric-product specificity and inhibitor binding (PMID:33764612, PMID:22219200, PMID:27480107). Notably, several PRMT6 functions are non-catalytic: it scaffolds IRF3 to block TBK1-IRF3 interaction and dampen type I interferon responses, and coactivates NF-κB through direct RelA binding (PMID:29973649, PMID:24939901). PRMT6 abundance is itself tuned by R35 automethylation governing stability, by CK2-mediated phosphorylation/deubiquitylation, and by the ubiquitin ligases FBXO24 and FBXW17 (PMID:23866860, PMID:33539787, PMID:32828318, PMID:33959602).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 2001 High

    Established PRMT6 as a distinct, exclusively nuclear type I arginine methyltransferase with its own automethylation activity, defining the enzyme class and setting it apart from PRMT1/PRMT4.

    Evidence GST fusion in vitro methylation, GFP-fusion localization, substrate specificity comparison

    PMID:11724789

    Open questions at the time
    • No physiological substrate identified at this stage
    • Automethylation site and its function not yet defined
  2. 2007 High

    Identified H3R2me2a as PRMT6's major chromatin mark and established the antagonism with H3K4me3 via WDR5 blockade, providing the core transcriptional repression mechanism.

    Evidence In vitro methylation, ChIP, knockdown/overexpression, reporter assays in differentiation model

    PMID:18079182

    Open questions at the time
    • How PRMT6 is recruited to specific promoters not defined
    • Genome-wide target scope unknown at this stage
  3. 2006 High

    Extended PRMT6 function to viral biology, showing it methylates HIV-1 Rev and Tat at arginine-rich motifs to impair RNA binding and viral replication, establishing non-histone substrate methylation as functionally consequential.

    Evidence In vitro methylation, co-IP, RNA export/reporter assays, mutagenesis, catalytically inactive mutant controls

    PMID:17176473 PMID:17267505

    Open questions at the time
    • Endogenous regulation of these methylations during infection unclear
    • Some PRMT6 effects on Rev are methylation-independent and mechanistically undefined
  4. 2012 High

    Connected PRMT6 chromatin activity to cell cycle and senescence control, showing H3R2me2a represses Trp53, p21, and p27, while PRMT6 also methylates p16 to blunt CDK inhibition.

    Evidence KO MEFs with genetic epistasis, promoter ChIP, cell cycle/senescence assays, in vitro methylation with mutagenesis

    PMID:22904064 PMID:22916108 PMID:22987071 PMID:23032699

    Open questions at the time
    • Recruitment determinants to these specific promoters not resolved
    • p16 methylation evidence rests on single-lab co-IP/methylation
  5. 2012 High

    Defined PRMT6's enzymatic mechanism as rapid-equilibrium random with dead-end complexes, clarifying how substrate and cofactor engage the active site.

    Evidence Initial velocity, product inhibition, and dead-end analog kinetic studies

    PMID:22219200

    Open questions at the time
    • Kinetics defined on peptide substrates only, not full-length proteins or nucleosomes
  6. 2013 High

    Identified R35 as the automethylation site required for PRMT6 protein stability, linking the enzyme's self-modification to its own abundance and antiviral function.

    Evidence LC-MS, mutagenesis, in vitro/in vivo methylation, HIV-1 infectivity assay

    PMID:23866860

    Open questions at the time
    • Mechanism by which R35 methylation stabilizes the protein unresolved
  7. 2014 High

    Revealed PRMT6 can act as a transcriptional coactivator by directly binding RelA and amplifying NF-κB signaling, expanding its role beyond repression.

    Evidence Transgenic gain-of-function mouse, co-IP, ChIP, NF-κB reporter, cytokine measurement

    PMID:24939901

    Open questions at the time
    • Whether coactivation requires catalytic activity not fully resolved
    • Target gene selectivity mechanism unclear
  8. 2016 High

    Provided crystal structures and inhibitor cocrystals defining the structural basis for asymmetric versus symmetric dimethylarginine product specificity and enabling rational inhibitor design.

    Evidence X-ray crystallography with SAH, bisubstrate and covalent inhibitors, methylation inhibition and kinetic assays

    PMID:27480107 PMID:32367723

    Open questions at the time
    • No structure with full-length protein substrate or nucleosome
    • Conformational basis of broad substrate tolerance not captured
  9. 2018 High

    Demonstrated catalysis-independent scaffold functions in immunity—blocking TBK1-IRF3 interaction—establishing that some PRMT6 roles do not require methyltransferase activity.

    Evidence PRMT6-/- mice, co-IP, IFN-β reporter, viral infection assays, methyltransferase-inactive mutant

    PMID:29973649

    Open questions at the time
    • Structural basis of IRF3 binding undefined
    • Balance between catalytic and scaffold roles in vivo unclear
  10. 2018 High

    Established context-dependent dual transcriptional output of H3R2me2a—repressive at promoters but supporting activation at enhancers—through KMT2A versus KMT2D recruitment during differentiation.

    Evidence PRMT6 KO cells, genome-wide ChIP-seq of H3R2me2a and multiple histone marks, differentiation assays

    PMID:30232013

    Open questions at the time
    • What determines promoter versus enhancer outcome at a given locus is unresolved
  11. 2019 High

    Expanded the non-histone substrate repertoire to key signaling nodes—PTEN R159 (PI3K-AKT), CRAF R100 (RAS-ERK), and FOXO3 (autophagy/atrophy)—positioning PRMT6 as a regulator of growth and metabolic signaling.

    Evidence MS site identification, co-IP, in vitro methylation, KO mouse and organoid models, signaling readouts

    PMID:30332648 PMID:30653406 PMID:30886105 PMID:31469916

    Open questions at the time
    • Stoichiometry and dynamics of these methylations in vivo not quantified
    • Cross-talk among the affected pathways not integrated
  12. 2020 High

    Defined mitotic functions of PRMT6, showing H3R2me2a recruits the Aurora B chromosomal passenger complex and that PRMT6-methylated RCC1 activates RAN GTPase, with CK2 stabilizing PRMT6.

    Evidence In vitro Aurora B binding/kinase assays, co-IP, MS, chromatin fractionation, xenograft models, CK2 kinase assay

    PMID:32001712 PMID:33539787

    Open questions at the time
    • Temporal coordination of these mitotic substrates not resolved
    • How CK2-PRMT6-RCC1 axis is triggered at mitotic entry unclear
  13. 2020 Medium

    Mapped multiple post-translational controls of PRMT6 abundance via FBXO24 (K369) and FBXW17-mediated ubiquitination, defining how the enzyme is turned over.

    Evidence Co-IP, ubiquitination and protein stability assays, proteasome inhibition, mutagenesis

    PMID:32828318 PMID:33959602

    Open questions at the time
    • Signals triggering each ligase not defined
    • Both rest on single-lab co-IP/stability assays without reciprocal validation
  14. 2021 High

    Characterized PRMT6 substrate preference (RG motif with basic/bulky flanking residues) and showed redundancy with CARM1 for H3R17me2a, refining the rules and partial overlap of its specificity.

    Evidence Targeted MS methylation with 204 H3 substitutions, in vitro methylation screen, CARM1/PRMT6 double-KO mouse genetics

    PMID:33008887 PMID:33764612

    Open questions at the time
    • Why some in vitro sites (e.g. H3R8) are not in vivo substrates not explained
    • Determinants of substrate selection beyond local sequence unclear
  15. 2021 High

    Extended PRMT6 function to neuronal homeostasis, showing huntingtin R118 methylation supports vesicle association and anterograde axonal transport, with PRMT6 overexpression rescuing HD models.

    Evidence In vitro methylation, mutagenesis, vesicle fractionation, live axonal transport imaging, HD fly and cell models

    PMID:33852844

    Open questions at the time
    • Whether endogenous PRMT6 levels limit transport in disease unclear
    • Link to other huntingtin modifications not addressed
  16. 2022 Medium

    Demonstrated direct metabolic enzyme regulation by PRMT6, methylating 6PGD and ENO1 to enhance pentose phosphate and glycolytic flux, broadening its role to metabolic reprogramming.

    Evidence In vitro methylation, mutagenesis, enzymatic activity and metabolic flux assays

    PMID:36815049

    Open questions at the time
    • In vivo contribution of these site-specific methylations not established
    • Single-lab evidence without orthogonal validation
  17. 2023 Medium

    Identified stable association with chromatin complexes—PARP1/CRL4B and PRMT5—and additional recruiting partners (LEF1, PELP1), clarifying how PRMT6 is brought to co-regulated target loci.

    Evidence MS, co-IP, GST pulldown, ChIP-seq, reporter and knockdown assays

    PMID:24447537 PMID:34001852 PMID:36400182 PMID:36941223

    Open questions at the time
    • Stoichiometry and architecture of these complexes undefined
    • Mostly single-lab co-IP/ChIP evidence
  18. 2024 Medium

    Established a recurring theme of PRMT6 promoting condensate/phase-separation behaviors and stabilizing oncoproteins via methylation—p62, AMPKα1, c-MYC, ALKBH5, HIF-1α—linking methylation to protein stability, signaling, and metabolism in disease.

    Evidence In vitro methylation, co-IP, ubiquitination assays, FRAP/PLA, KO mice and xenograft models

    PMID:37178510 PMID:38402915 PMID:38466502 PMID:38994016 PMID:39819457

    Open questions at the time
    • Direct demonstration of methylation-driven phase separation in vivo limited
    • Each substrate characterized by a single lab without independent replication
  19. 2025 Medium

    Showed PRMT6 is a direct pharmacological target whose inhibition (metformin binding; EPZ020411, MS023 tool compounds) reverses H3R2me2a-dependent programs, validating the enzyme for therapeutic intervention.

    Evidence Direct binding assay, in vitro inhibition, UHRF1 chromatin fractionation, DNA methylation and cell cycle analysis, xenograft models

    PMID:26101569 PMID:41327885

    Open questions at the time
    • Selectivity of metformin for PRMT6 in vivo not fully established
    • Therapeutic window across the enzyme's many functions unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how PRMT6's catalytic versus non-catalytic (scaffold) activities are partitioned in vivo, and what governs the locus-specific choice between transcriptional repression and activation.
  • No unified model linking recruitment partners to repressive vs activating output
  • Relative in vivo contribution of the many reported non-histone substrates unquantified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0140096 catalytic activity, acting on a protein 5 GO:0042393 histone binding 4 GO:0140110 transcription regulator activity 4 GO:0060090 molecular adaptor activity 2
Localization
GO:0000228 nuclear chromosome 3 GO:0005634 nucleus 1
Pathway
R-HSA-1430728 Metabolism 4 R-HSA-162582 Signal Transduction 4 R-HSA-1640170 Cell Cycle 4 R-HSA-168256 Immune System 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-9612973 Autophagy 3
Partners
CRAFIRF3LEF1PRMT5PTENRCC1RELAWDR5
Complex memberships
NF-κB (RelA) coactivator complexPRMT6/PARP1/CRL4Bchromosomal passenger complex (CPC) recruitment via H3R2me2a

Evidence

Reading pass · 64 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 PRMT6 is a nuclear type I protein arginine methyltransferase that catalyzes both omega-N(G)-monomethylarginine and asymmetric omega-N(G),N(G)-dimethylarginine on glycine- and arginine-rich substrates in a processive manner, and is the first PRMT to display automethylation activity. It resides solely in the nucleus when fused to GFP and has distinct substrate specificity compared to PRMT1 and PRMT4. GST fusion protein in vitro methylation assay, GFP fusion subcellular localization, substrate specificity comparison The Journal of biological chemistry High 11724789
2007 PRMT6 methylates histone H3 at R2 (H3R2me2a) in vitro and in vivo and is the major H3R2 methyltransferase in cells. H3R2 methylation by PRMT6 inhibits H3K4 trimethylation by blocking WDR5 (a subunit of the MLL complex) binding to H3 in vitro, thereby repressing transcription of Hox and Myc-dependent genes. Upon retinoic acid-induced transcriptional activation, PRMT6 recruitment and H3R2me2a decrease while H3K4me3 increases. In vitro histone methylation assay, overexpression/knockdown analysis, ChIP, reporter assays, cell differentiation model Genes & development High 18079182
2007 PRMT6 methylates HIV-1 Tat at R52 and R53, reducing Tat binding to TAR RNA and impairing Tat-TAR-cyclin T1 ternary complex formation, thereby reducing cyclin T1-dependent Tat transcriptional activation. A methylase-inactive PRMT6 mutant did not reduce Tat transactivation. PRMT6 knockdown increased HIV-1 production. In vitro and in vivo methylation assay, site-directed mutagenesis, luciferase/CAT reporter assays, siRNA knockdown, cell-based HIV replication assay Journal of virology High 17267505
2006 PRMT6 methylates HIV-1 Rev at a single arginine in its N-terminal arginine-rich motif, reducing Rev binding to the RRE and Rev-mediated viral RNA export from nucleus to cytoplasm. Wild-type but not methylase-inactive PRMT6 reduced Rev-RRE binding and export. PRMT6 also reduces Rev protein levels through a post-translational mechanism independent of methyltransferase activity. In vitro methylation assay, co-immunoprecipitation, CAT reporter RNA export assay, site-directed mutagenesis of Rev arginines Retrovirology High 17176473
2009 PRMT6 directly represses the thrombospondin-1 (TSP-1) promoter by associating with it and maintaining H3R2me2a while suppressing H3K4me3. In PRMT6-deficient cells H3R2 is hypomethylated and H3K4 trimethylated at the TSP-1 promoter, leading to TSP-1 upregulation and cell migration defects that are rescued by blocking secreted TSP-1. ChIP, microarray, siRNA knockdown, TSP-1 promoter reporter assay, cell migration assay, neutralizing antibody rescue The Journal of biological chemistry High 19509293
2011 PRMT6 catalyzes H2AR29 asymmetric dimethylation (H2AR29me2), a novel repressive histone mark enriched at PRMT6-repressed genes. PRMT1 and PRMT6 are unique among PRMTs in methylating H2A at R11 and R29. Biochemical methylation assay with candidate enzymes, mass spectrometry identification of methylation sites, ChIP at repressed genes Epigenetics & chromatin High 21774791
2012 PRMT6 knockout MEFs undergo premature senescence via p53-dependent induction of p53, p21, and PML. ChIP revealed PRMT6 and H3R2me2a enrichment at the Trp53 upstream region; in PRMT6-/- MEFs this mark is lost, H3K4me3 increases, and p53 transcription rises. Double KO with p53 prevents senescence, placing PRMT6 upstream of p53. PRMT6-/- MEF generation, ChIP, genetic epistasis (PRMT6-/-;p53-/- double KO), growth assays Nucleic acids research High 22904064
2012 PRMT6 directly represses the p21 (CDKN1A) promoter via H3R2me2a in a p53-independent manner. PRMT6 knockdown in breast cancer cells causes p21 derepression, G1 arrest, and cellular senescence; bypassing p21-mediated arrest rescues these phenotypes. siRNA knockdown, promoter ChIP, cell cycle analysis, senescence assays, soft agar and xenograft assays, rescue by p21 bypass Nucleic acids research High 22987071
2012 PRMT6 represses p21 and p27 gene expression through H3R2me2a deposited at their promoters, regulating cell cycle progression; knockdown of PRMT6 causes G2 arrest in U2OS cells with upregulation of p21 and p27. In oncogene-induced senescence, PRMT6 expression declines and p21 rises; PRMT6 overexpression reduces OIS. siRNA knockdown, ChIP, cell cycle analysis, OIS cell model, promoter analysis PloS one High 22916108
2012 PRMT6 methylates the tumor suppressor p16 (INK4A) at R22, R131, and R138, reducing p16-CDK4 association and counteracting G1 cell cycle arrest induced by p16. In vitro methylation assay, site-directed mutagenesis, co-immunoprecipitation, flow cytometry, Western blot The international journal of biochemistry & cell biology Medium 23032699
2012 PRMT6 uses a rapid equilibrium random kinetic mechanism (not ordered) with dead-end EAP and EBQ complexes, as determined with the AcH4-21 and R1 peptides and their monomethylated versions. Initial velocity, product inhibition, and dead-end analog inhibition kinetic studies The Journal of biological chemistry High 22219200
2013 PRMT6 automethylates at R35 (identified by LC-MS and confirmed by mutagenesis). Automethylation at R35 is required for PRMT6 protein stability and its anti-HIV-1 activity in single-cycle infectivity assays. LC-MS, site-directed mutagenesis, in vitro and in vivo methylation assays, HIV-1 TZM-bl infectivity assay Retrovirology High 23866860
2013 PELP1 interacts with PRMT6 and co-regulates alternative splicing and estrogen receptor target gene expression; PRMT6 inhibition reduces PELP1-mediated ER activation, proliferation, and colony formation. PELP1 and PRMT6 co-occupy ER target gene promoters affecting H3R2me2a. Co-immunoprecipitation, RNA-seq, ChIP, reporter assays, siRNA knockdown, proliferation/colony assays Molecular oncology Medium 24447537
2013 PRMT6 methylates GPS2, facilitating its interaction with TBL1 and protecting GPS2 from Siah2-mediated polyubiquitination and proteasomal degradation, thereby regulating GPS2 nuclear function. Co-immunoprecipitation, ubiquitination assay, methylation assay, protein stability assay The Journal of biological chemistry Medium 26070566
2013 PRMT6 differentially regulates MHC class II isotype expression: through an AT-hook motif of RFX5, PRMT6 downregulates HLA-DQ but not HLA-DR transcription in an AT-hook-dependent manner. Promoter reporter assay, methylation analysis, mutant RFX5 constructs, gene expression analysis Molecular immunology Medium 23911394
2013 Yeast two-hybrid screen and in vitro methylation assays identified 36 putative PRMT6 partners; 7 were validated by co-IP in vivo; 4 new substrates were confirmed including HMGA1a. HMGA1a modulates PRMT6 methyltransferase activity. Yeast two-hybrid, co-immunoprecipitation, in vitro methylation assay PloS one Medium 23326497
2014 PRMT6 functions as a NF-κB coactivator: it directly interacts with RelA, is recruited by RelA to selective NF-κB target promoters upon TNF-α stimulation, enhances NF-κB reporter transcriptional activity, and causes RelA nuclear accumulation. In a tamoxifen-inducible transgenic mouse model, ER*-PRMT6 activation increases IL-6 levels. Transgenic mouse gain-of-function model, co-immunoprecipitation, ChIP, NF-κB reporter assay, cytokine measurement Nucleic acids research High 24939901
2015 PRMT6 methylates p21 (CDKN1A) at R156 and promotes phosphorylation of T145, resulting in increased cytoplasmic localization of p21 and resistance to cytotoxic agents. In vitro methylation assay, site-directed mutagenesis, subcellular fractionation, cell viability assay Oncotarget Medium 26436589
2015 PRMT6 inhibits HIV-1 Tat nucleolar retention in a methylation-dependent manner: overexpression of catalytically active (but not inactive) PRMT6 excludes Tat from the nucleolus; R52/53A Tat mutant does not show redistribution. FRAP analysis indicates Tat nucleolar accumulation is through binding to nucleolar components, blocked by PRMT6 methylation at R52/53. Fluorescence microscopy, FRAP, site-directed mutagenesis, catalytically inactive mutant control Biochimica et biophysica acta Medium 26611710
2015 EPZ020411 was identified as the first potent, selective small-molecule PRMT6 inhibitor tool compound with good bioavailability following subcutaneous dosing in rats. Biochemical inhibitor assay, selectivity profiling, pharmacokinetic measurement in rats ACS medicinal chemistry letters Medium 26101569
2015 PRMT6 is required for zebrafish early development (epiboly); it directly represses gadd45αa via H3R2me2a, and loss of PRMT6 activates p38/JNK pathway and apoptosis. gadd45αa morpholino and p38/JNK inhibitors partially rescue prmt6 morphant defects. Morpholino knockdown in zebrafish, mRNA rescue, microarray, ChIP-qPCR, luciferase reporter, pharmacological inhibitors The Journal of biological chemistry High 26487724
2016 Crystal structures of human PRMT6 in complex with SAH, a bisubstrate inhibitor (GMS), and an arginine-containing peptide were solved. Structural analysis reveals the determinants of asymmetric vs. symmetric dimethylarginine product specificity among PRMT types. X-ray crystallography, bisubstrate inhibitor synthesis, in vitro methylation inhibition assay The Biochemical journal High 27480107
2017 PRMT6 overexpression impairs chromatin association of UHRF1 (an accessory factor of DNMT1), likely via elevated H3R2me2a inhibiting UHRF1-H3 interaction, resulting in passive DNA demethylation and global DNA hypomethylation in cancer. Overexpression/knockdown studies, bisulfite sequencing for DNA methylation, chromatin fractionation, co-IP, UHRF1-H3 interaction assay Cell reports Medium 29262320
2018 PRMT6 methylates CRAF at arginine 100 (R100), decreasing CRAF's RAS binding potential and altering downstream MEK/ERK signaling; loss of PRMT6 promotes hepatocellular carcinoma stem cell properties. Co-immunoprecipitation, in vitro methylation assay, mass spectrometry, PRMT6 KO mouse model, organoid culture, transcriptome/protein-protein interaction analysis Cell reports High 30332648
2018 PRMT6 inhibits antiviral innate immunity by binding IRF3 and blocking TBK1-IRF3 interaction, thereby inhibiting IRF3 activation and type-I interferon production. This function is independent of PRMT6 methyltransferase activity. PRMT6-deficient mice show enhanced antiviral immunity. PRMT6-/- mouse generation, co-immunoprecipitation, IFN-β reporter assay, viral infection assays, methyltransferase-inactive mutant Cellular & molecular immunology High 29973649
2018 PRMT6 is recruited to H3R2me2a-marked promoters and enhancers during neural differentiation; loss of H3R2me2a at promoters leads to enhanced KMT2A binding and H3K4me3, increasing transcription, while loss at enhancers leads to reduced KMT2D binding and H3K4me1/H3K27ac, decreasing transcription—indicating context-dependent dual transcriptional roles. PRMT6 KO cell model, ChIP-seq, H3R2me2a genome-wide mapping, differentiation assays Cell reports High 30232013
2019 PRMT6 physically associates with PTEN and asymmetrically dimethylates it at R159, suppressing PI3K-AKT signaling. PTEN R159K mutant found in cancers loses its ability to inhibit PI3K-AKT. PRMT6-mediated PTEN methylation also modulates pre-mRNA alternative splicing. Mass spectrometry, co-immunoprecipitation, in vitro methylation assay, PI3K-AKT signaling readouts, transcriptome analysis Proceedings of the National Academy of Sciences of the United States of America High 30886105
2019 In the absence of PRMT1, increased PRMT6 specifically methylates FOXO3 at R188 and R249, activating FOXO3 and driving muscle atrophy through upregulation of autophagy markers and muscle-specific ubiquitin ligases. PRMT6 depletion abrogates FOXO3 hyperactivation in PRMT1-deficient muscle. Muscle-specific PRMT1 KO mice, adenovirus-delivered siRNA, in vitro methylation, site-directed mutagenesis, gene expression analysis Autophagy High 30653406
2019 PPARα loss promotes colon carcinogenesis by increasing PRMT6 expression (via retinoblastoma protein depletion), and PRMT6 represses p27 expression through H3R2 dimethylation at its promoter. Intestine-specific Ppara KO mice, immunoblots, ChIP (implied by H3R2 dimethylation-mediated repression), colon cancer model Gastroenterology Medium 31154022
2019 PRMT6 promotes alternate activation of tumor-associated macrophages via a non-catalytic interaction with ILF2, identifying macrophage migration inhibitory factor as a downstream target of PRMT6-ILF2 signaling. Proteomics, in vitro gain/loss-of-function, lung-targeted PRMT6 transgenic mouse, co-immunoprecipitation Molecular cancer research : MCR Medium 31619507
2020 PRMT6 methylates CRAF at R100, and this methylation interferes with RAS/RAF binding, altering ERK-mediated PKM2 nuclear translocation and driving aerobic glycolysis (Warburg effect) in hepatocellular carcinoma. PRMT6 loss upregulates MFSD2A via reduced H3R2me2a, increasing docosahexaenoic acid levels. In vitro gain/loss-of-function, patient-derived organoids, PET-MRI animal models, PRMT6 KO HCC mouse model, transcriptome analysis Hepatology (Baltimore, Md.) High 31469916
2020 H3R2me2a deposited by PRMT6 recruits the chromosomal passenger complex (CPC/Aurora B) to chromosome arms upon mitotic entry, facilitating H3S10 phosphorylation by Aurora B and chromosome condensation. In vitro, Aurora B preferentially binds H3 peptide containing H3R2me2a and phosphorylates H3S10. In vitro Aurora B binding and kinase assay with H3 peptides, cell-based CPC localization studies, ChIP, PRMT6 manipulation Nature communications High 32001712
2020 PRMT6 methylates FOXO3 to regulate autophagy and protein degradation, and this is upstream of the PRMT1-PRMT6-FOXO3 axis; additionally PRMT6 is degraded by the F-box protein FBXO24 via polyubiquitination of K369, with the K369R mutant resistant to degradation. Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis, cell proliferation/migration assay Biochemical and biophysical research communications Medium 32828318
2020 PRMT6 is also degraded via FBXW17-mediated polyubiquitination in a CSE-induced COPD context: FBXW17 selectively binds PRMT6 in nuclei and targets it for proteasomal degradation; proteasome inhibition or FBXW17 silencing abrogates PRMT6 loss. Co-immunoprecipitation, proteasome inhibitor treatment, siRNA knockdown, protein stability assay Frontiers in cell and developmental biology Medium 33959602
2020 PRMT6 depletion in HCC cells increases PTEN and PI3K regulatory subunit p85 levels but decreases PDK1, causing AKT dephosphorylation and lung epithelial cell death; PRMT6 overexpression reverses CSE-induced cell death via PI3K/AKT signaling. PRMT6 KO and overexpression, Western blot for PI3K/AKT components, cell death/survival assays Aging Medium 33260152
2020 PRMT6 deficiency in HCC promotes autophagy by preventing methylation of BAG5: PRMT6 physically interacts with and methylates BAG5, enhancing degradation of its partner HSC70 (an autophagy chaperone). Loss of PRMT6 stabilizes HSC70 and promotes autophagic flux. Co-immunoprecipitation, methylation assay, autophagy flux analysis, in vivo xenograft model Cancer letters Medium 33186656
2020 PRMT6 is functionally redundant with CARM1 for H3R17me2a deposition: PRMT6 can deposit the H3R17me2a mark in vitro. CARM1/PRMT6 double KO embryos are smaller than CARM1 KO alone and MEFs show absence of mitotic H3R17me2a; combination inhibition of CARM1 and PRMT6 synergistically suppresses cell proliferation. In vitro methylation assay screen, double KO mouse genetics, MEF analysis, combination inhibitor treatment The Journal of biological chemistry High 33008887
2021 PRMT6 methylates RCC1 (regulator of chromatin condensation 1) to promote RCC1 association with chromatin and activation of RAN GTPase, which is required for mitosis. CK2 phosphorylates and stabilizes PRMT6 through deubiquitylation. Disruption of CK2-PRMT6-RCC1 signaling causes mitotic defects and reduces GSC tumorigenicity. PRMT6 inhibitor EPZ020411 suppresses RCC1 methylation and enhances radiotherapy in brain tumor xenografts. Co-immunoprecipitation, in vitro methylation assay, MS, CK2 kinase assay, chromatin fractionation, xenograft model, PRMT6 inhibitor Molecular cell High 33539787
2021 PRMT6 methylates huntingtin (HTT) at R118; without R118 methylation, HTT associates less with vesicles, anterograde axonal trafficking is diminished, and neuronal death occurs. Overexpressing PRMT6 restores axonal transport and neuronal viability in HD models; in HD flies overexpressing PRMT6 rescues axonal defects. In vitro methylation assay, site-directed mutagenesis, vesicle fractionation, live axonal transport imaging, HD fly model, HD cell model Cell reports High 33852844
2021 LEF1 is an interaction partner of PRMT6, recruiting it to the CCND1 (Cyclin D1) promoter. Knockdown of LEF1 or PRMT6 reduces CCND1 expression and increases cells in G1 phase. Co-immunoprecipitation, ChIP, siRNA knockdown, cell cycle analysis, gene expression analysis Oncogenesis Medium 34001852
2021 PRMT6 regulates widespread alternative splicing changes in NT2/D1 neural pluripotent cells primarily in an H3R2me2a-independent manner; only a small subset of PRMT6-dependent splicing events correlate with H3R2me2a at splice sites. PRMT6 KO, RNA-seq for splicing, H3R2me2a ChIP-seq comparison with splice site locations Life science alliance Medium 39900436
2021 PRMT6 substrate recognition is broad with preference for RG motif (not RGG) and basic/bulky residues near the target arginine. PRMT6 methylates both R2 and R8 in the H3 tail peptide in vitro but H3R8 is not an in vivo substrate. Targeted mass spectrometry-based methylation assay with 204 amino acid substitutions in H3 peptide, in vitro methylation The FEBS journal High 33764612
2022 PRMT6 methylates 6PGD at R324 to enhance its enzymatic activity, and methylates ENO1 at R9 (promoting active dimer formation) and R372 (promoting 2-PG substrate binding), thereby regulating oxidative pentose phosphate pathway and glycolysis in lung cancer cells. In vitro methylation assay, site-directed mutagenesis, enzymatic activity assays for 6PGD and ENO1, metabolic flux analysis Acta pharmaceutica Sinica. B Medium 36815049
2022 IGF2BP2 stabilizes PRMT6 mRNA via m6A-mediated manner; PRMT6 catalyzes H3R2me2a to suppress MFSD2A expression; PRMT6 loss upregulates MFSD2A, increasing docosahexaenoic acid and impairing AML leukemia stem cell maintenance. m6A-seq/meRIP-seq, RNA-seq, genetic deletion, pharmacological inhibition, ChIP for H3R2me2a at MFSD2A promoter Cell stem cell High 36574771
2022 PRMT6 functionally associates with PRMT5; H3R2me2a deposited by PRMT6 co-localizes with PRMT5-mediated H4R3me2s and H3R8me2s at promoters of CDKN2B and CCNG1, co-repressing these genes in colorectal cancer. PRMT5 was identified as a physical interaction partner of PRMT6 by mass spectrometry and co-IP. Mass spectrometry, co-immunoprecipitation, GST pulldown, RNA-seq, ChIP, siRNA knockdown Experimental cell research Medium 36400182
2023 PRMT6 asymmetrically dimethylates STAT3 at R729 (STAT3 R729me2a), which is required for STAT3 membrane localization, interaction with JAK2, Y705 phosphorylation, and PRMT6-driven breast cancer cell metastasis. Co-immunoprecipitation, in vitro methylation assay, site-directed mutagenesis, subcellular fractionation, in vivo metastasis assay, PRMT6 inhibitor Cell death & disease Medium 37813837
2023 PRMT6 maintains CDC20 transcription via H3R2me2a; CDC20 then interacts with and promotes proteasomal degradation of CDKN1B (p27), driving GBM cell proliferation. This PRMT6-CDC20-CDKN1B axis was confirmed by rescue experiments. ChIP, co-immunoprecipitation, knockdown/rescue experiments, cell cycle analysis, ubiquitination assay Oncogene Medium 36792756
2023 LSD1 and PRMT6 are overexpressed in an androgen-dependent manner in skeletal muscle of SBMA patients/mice, cooperatively and synergistically transactivate androgen receptor, and their effect is enhanced by expanded polyQ. miRNA-mediated co-silencing of LSD1 and PRMT6 attenuates disease in SBMA mice. Patient/mouse tissue analysis, cell lines, co-transactivation assays, SBMA fly model, miRNA-mediated silencing in SBMA mice Nature communications Medium 36746939
2023 PRMT6 forms a transcription-repressive complex with PARP1 and CRL4B at the PER3 circadian clock gene promoter; genome-wide analysis shows PRMT6/PARP1/CUL4B co-occupy genes involved in circadian rhythms to promote breast cancer proliferation and metastasis. Co-immunoprecipitation, ChIP-seq, reporter assays, PARP1 inhibitor treatment Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 36941223
2024 PRMT6 methylates STING, inactivating it and reducing TBK1 and IRF3 phosphorylation, thereby diminishing type I interferon production and antiviral innate immunity in HSV-1 infection. PRMT6 KO mice, in vitro methylation assay, co-immunoprecipitation, phosphorylation assays, viral load measurement, PRMT6 inhibitor administration Brain : a journal of neurology Medium 38366606
2024 PRMT6 interacts with STAT1 to jointly regulate ACSL1 transcription; PRMT6 reduction in diabetic nephropathy induces lipid peroxidation by upregulating ACSL1, contributing to ferroptosis. STAT1 inhibition with fludarabine delays DN progression. PRMT6 KO mice, transcriptomic/lipidomic analysis, co-immunoprecipitation, ChIP, pharmacological STAT1 inhibition Cell death and differentiation Medium 39134684
2024 PRMT6 methylates AMPKα1 at R403; PRMT6 directly interacts with and methylates AMPKα1 in vitro without other cellular components. PRMT6-mediated methylation promotes AMPKα1 phase separation and puncta formation in cells. In vitro methylation assay, co-immunoprecipitation, truncated/point mutant analysis, immunocytochemistry Biochemical and biophysical research communications Medium 37178510
2024 PRMT6 methylates ALKBH5 at R283, which inhibits Indisulam-induced ubiquitination and proteasomal degradation of RBM39, increases RBM39 levels, and promotes alternative splicing of proto-oncogenes, driving Indisulam resistance in NSCLC. In vitro methylation assay, co-immunoprecipitation, ubiquitination assay, RNA-seq for splicing, xenograft model, PRMT6 inhibitor (MS023) PLoS biology Medium 40465651
2024 PRMT6 mediates p62 asymmetric dimethylarginine (ADMA) modification, increasing p62 oligomerization and phase separation, promoting p62 body formation that sequesters Keap1 to activate Nrf2 signaling, forming a negative feedback loop during ferroptosis. Co-immunoprecipitation, proximal ligation assay, FRAP for phase separation, in vitro methylation, xenograft model Theranostics Medium 38994016
2024 PRMT6 forms a coactivation complex with NF-κB and catalyzes H3R17 asymmetric dimethylation at the Ccl2 promoter in macrophages, transcriptionally upregulating CCL2 to amplify macrophage chemotactic signaling and heterotopic ossification. ChIP, co-immunoprecipitation, macrophage-specific PRMT6 KO mice, CCL2 supplementation rescue, HO mouse model Bone research Medium 41803087
2024 PRMT6 directly methylates ALKBH5 at R283, which promotes breast tumor growth; methylation of ALKBH5 by PRMT6 increases LDHA RNA stability via m6A demethylation, leading to increased aerobic glycolysis. Confirmed in PRMT6-KO mice. In vitro methylation assay, PRMT6 KO mice, m6A analysis, RNA stability assay, glycolysis measurement Frontiers of medicine Medium 38466502
2024 PRMT6 inhibits TRAF6 transcription via H3R2me2a at the TRAF6 promoter, reducing TRAF6-EZH2 interaction and enhancing EZH2 protein stability, thereby promoting glioblastoma invasion and migration. ChIP, co-immunoprecipitation, ubiquitination assay, knockdown/overexpression, xenograft model Cell death & disease Medium 39043634
2024 Prmt6 deficiency reduces H3R2me2a at promoters of Ppard, Acox3, and Cpt1a (fatty acid oxidation genes), increasing chromatin accessibility and shifting osteoclast metabolism toward fatty acid oxidation rather than glycolysis, thereby suppressing osteoclastogenesis. PRMT6 KO mice (OVX model), ATAC-seq, ChIP for H3R2me2a, metabolic assays, PRMT6 inhibitor Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 39120025
2024 PRMT6 interacts with HIF-1α and methylates it, increasing HIF-1α protein stability, thereby promoting glycolysis and neuroinflammation in spinal cord microglia and exacerbating neuropathic pain. Co-immunoprecipitation, protein stability assay, PRMT6 KO/knockdown/overexpression, glycolysis and inflammation assays, in vivo CCI mouse model Brain, behavior, and immunity Medium 38402915
2024 A chimeric PRMT6 protein (PRMT6MT2B2) formed by an endogenous retroviral LTR promoter increases H2AR3me2a but not H4R3me2a (unlike canonical PRMT6 which increases both), and promotes epiblast cell fate in mouse preimplantation embryos when expressed in one blastomere. Overexpression in fibroblasts and mouse two-cell embryos, histone modification Western blot, blastocyst lineage analysis Biology of reproduction Medium 38196172
2025 Metformin directly binds PRMT6 and inhibits its H3R2 methylation activity, thereby enhancing chromatin association of UHRF1, promoting DNA methylation, repressing DNA replication-associated genes, and inducing cell cycle arrest in breast cancer cells. Genetic disruption of metformin-PRMT6 interaction attenuates metformin's inhibitory effect. Direct binding assay, in vitro methylation inhibition, UHRF1 chromatin fractionation, DNA methylation analysis, cell cycle analysis, xenograft model Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 41327885
2025 PRMT6 mono-methylates c-MYC at R371, inhibiting its poly-ubiquitination and proteasomal degradation, thereby stabilizing c-MYC protein and promoting colorectal cancer cell proliferation. In vitro methylation assay, co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis, xenograft model Journal of translational medicine Medium 39819457
2024 A GATA1 frameshift mutation enhances its recruitment of PRMT6, which deposits H3R2me2a at GATA1 target gene regulatory elements, repressing transcription and impairing erythroid differentiation; PRMT6 inhibitor MS023 partially rescues impaired erythroid differentiation. Proximity labeling/mass spectrometry, co-immunoprecipitation, ChIP, PRMT6 inhibitor treatment, erythroid differentiation assay Haematologica Medium 38385251
2020 The first cocrystal structure of PRMT6 bound to a covalent inhibitor (MS117) was solved, confirming covalent binding mode by mass spectrometry and kinetic studies. The structure reveals the binding mode of a cysteine-reactive compound distinct from reversible PRMT inhibitors. X-ray cocrystal structure, mass spectrometry, kinetic analysis, selectivity profiling Journal of medicinal chemistry High 32367723

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. The Journal of biological chemistry 296 11724789
2011 Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. International journal of cancer 257 20473859
2007 PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes & development 243 18079182
2019 Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology 145 31154022
2007 Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. Journal of virology 114 17267505
2021 PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Molecular cell 107 33539787
2020 CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. Hepatology (Baltimore, Md.) 107 31469916
2019 Skeletal muscle-specific Prmt1 deletion causes muscle atrophy via deregulation of the PRMT6-FOXO3 axis. Autophagy 104 30653406
2015 Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS medicinal chemistry letters 101 26101569
2018 PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell reports 93 30332648
2012 p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6. Nucleic acids research 90 22987071
2012 Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor. Nucleic acids research 89 22904064
2011 Methylation of H2AR29 is a novel repressive PRMT6 target. Epigenetics & chromatin 81 21774791
2012 The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes. Nucleic acids research 80 22904088
2021 The N6-methyladenosine demethylase ALKBH5 negatively regulates the osteogenic differentiation of mesenchymal stem cells through PRMT6. Cell death & disease 69 34088896
2019 PTEN arginine methylation by PRMT6 suppresses PI3K-AKT signaling and modulates pre-mRNA splicing. Proceedings of the National Academy of Sciences of the United States of America 66 30886105
2022 Decoding m6A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. Cell stem cell 61 36574771
2022 PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism. Acta pharmaceutica Sinica. B 60 36815049
2018 The methyltransferase PRMT6 attenuates antiviral innate immunity by blocking TBK1-IRF3 signaling. Cellular & molecular immunology 59 29973649
2017 The Arginine Methyltransferase PRMT6 Regulates DNA Methylation and Contributes to Global DNA Hypomethylation in Cancer. Cell reports 59 29262320
2012 Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. PloS one 58 22916108
2006 PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. Retrovirology 58 17176473
2013 Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity. Retrovirology 55 23866860
2018 Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes. Cell reports 53 30232013
2009 Thrombospondin-1 is a transcriptional repression target of PRMT6. The Journal of biological chemistry 53 19509293
2014 A gain-of-function mouse model identifies PRMT6 as a NF-κB coactivator. Nucleic acids research 52 24939901
2020 PRMT6-mediated H3R2me2a guides Aurora B to chromosome arms for proper chromosome segregation. Nature communications 51 32001712
2022 The Emerging Role of PRMT6 in Cancer. Frontiers in oncology 50 35311114
2016 Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget 46 27323813
2019 PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages. Molecular cancer research : MCR 45 31619507
2015 PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget 45 26436589
2024 The PRMT6/STAT1/ACSL1 axis promotes ferroptosis in diabetic nephropathy. Cell death and differentiation 39 39134684
2020 Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6. The Journal of biological chemistry 38 33008887
2023 PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell death & disease 37 37813837
2024 PRMT6 deficiency or inhibition alleviates neuropathic pain by decreasing glycolysis and inflammation in microglia. Brain, behavior, and immunity 35 38402915
2024 PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration, invasion, and emt via the wnt-β-catenin pathway. Journal of experimental & clinical cancer research : CR 35 38637831
2020 Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor. Journal of medicinal chemistry 35 32367723
2016 Structural basis of arginine asymmetrical dimethylation by PRMT6. The Biochemical journal 34 27480107
2019 Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression. Carcinogenesis 33 30508037
2012 Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6). The Journal of biological chemistry 33 22219200
2012 Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability to arrest A549 cell proliferation. The international journal of biochemistry & cell biology 32 23032699
2013 PELP1 oncogenic functions involve alternative splicing via PRMT6. Molecular oncology 31 24447537
2023 PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B. Oncogene 29 36792756
2020 Cigarette smoke extract induces airway epithelial cell death via repressing PRMT6/AKT signaling. Aging 29 33260152
2024 PRMT6 Epigenetically Drives Metabolic Switch from Fatty Acid Oxidation toward Glycolysis and Promotes Osteoclast Differentiation During Osteoporosis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 28 39120025
2021 Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. Cell reports 28 33852844
2020 PRMT6 deficiency induces autophagy in hostile microenvironments of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability. Cancer letters 28 33186656
2023 The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 26 36941223
2021 PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. Oncogenesis 26 34001852
2013 PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: its implication in motility and invasion. Biochemical and biophysical research communications 26 23380452
2024 HSV-1 reactivation results in post-herpetic neuralgia by upregulating Prmt6 and inhibiting cGAS-STING. Brain : a journal of neurology 24 38366606
2020 PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18. Molecular medicine reports 23 32945431
2020 PRMT6 mediates inflammation via activation of the NF-κB/p65 pathway on a cigarette smoke extract-induced murine emphysema model. Tobacco induced diseases 22 32047419
2015 Protein Arginine Methyltransferase 6 (Prmt6) Is Essential for Early Zebrafish Development through the Direct Suppression of gadd45αa Stress Sensor Gene. The Journal of biological chemistry 22 26487724
2023 LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice. Nature communications 21 36746939
2019 Black carp PRMT6 inhibits TBK1-IRF3/7 signaling during the antiviral innate immune activation. Fish & shellfish immunology 21 31326582
2015 Exchange Factor TBL1 and Arginine Methyltransferase PRMT6 Cooperate in Protecting G Protein Pathway Suppressor 2 (GPS2) from Proteasomal Degradation. The Journal of biological chemistry 21 26070566
2014 PRMT6 mediates CSE induced inflammation and apoptosis. International immunopharmacology 20 25481537
2014 Association study between polymorphisms of PRMT6, PEX10, SOX5, and nonobstructive azoospermia in the Han Chinese population. Biology of reproduction 19 24648396
2024 circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation. Leukemia 16 38424136
2015 The protein arginine methyltransferase PRMT6 inhibits HIV-1 Tat nucleolar retention. Biochimica et biophysica acta 16 26611710
2024 PRMT6 facilitates EZH2 protein stability by inhibiting TRAF6-mediated ubiquitination degradation to promote glioblastoma cell invasion and migration. Cell death & disease 14 39043634
2022 PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1. Experimental cell research 14 36400182
2018 Upregulation of PRMT6 by LPS suppresses Klotho expression through interaction with NF-κB in glomerular mesangial cells. Journal of cellular biochemistry 14 29131380
2018 Significant association of PRMT6 hypomethylation with colorectal cancer. Journal of clinical laboratory analysis 14 29927001
2021 Systematic investigation of PRMT6 substrate recognition reveals broad specificity with a preference for an RG motif or basic and bulky residues. The FEBS journal 13 33764612
2021 F-Box Protein FBXW17-Mediated Proteasomal Degradation of Protein Methyltransferase PRMT6 Exaggerates CSE-Induced Lung Epithelial Inflammation and Apoptosis. Frontiers in cell and developmental biology 13 33959602
2024 Arginine methylation of ALKBH5 by PRMT6 promotes breast tumorigenesis via LDHA-mediated glycolysis. Frontiers of medicine 12 38466502
2020 SCF-FBXO24 regulates cell proliferation by mediating ubiquitination and degradation of PRMT6. Biochemical and biophysical research communications 12 32828318
2017 The protective effect of PRMT6 overexpression on cigarette smoke extract-induced murine emphysema model. International journal of chronic obstructive pulmonary disease 12 29138553
2013 Contributions of the histone arginine methyltransferase PRMT6 to the epigenetic function of RUNX1. Critical reviews in eukaryotic gene expression 12 23879542
2022 Design, synthesis and evaluation of antitumor activity of selective PRMT6 inhibitors. European journal of medicinal chemistry 11 36566712
2013 Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6. Virology journal 11 23800116
2013 Differential regulation of MHCII genes by PRMT6, via an AT-hook motif of RFX5. Molecular immunology 10 23911394
2024 Prmt6 represses the pro-adipogenic Ppar-gamma-C/ebp-alpha transcription factor loop. Scientific reports 9 38509237
2024 PRMT6-mediated ADMA promotes p62 phase separation to form a negative feedback loop in ferroptosis. Theranostics 9 38994016
2013 Identification and characterization of new molecular partners for the protein arginine methyltransferase 6 (PRMT6). PloS one 9 23326497
2024 Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6). Bioorganic chemistry 7 38754310
2022 Grass carp PRMT6 negatively regulates innate immunity by inhibiting the TBK1/IRF3 binding and cutting down IRF3 phosphorylation level. Developmental and comparative immunology 7 35033573
2022 PRMT6/LMNA/CXCL12 signaling pathway regulated the osteo/odontogenic differentiation ability in dental stem cells isolated from apical papilla. Cell and tissue research 7 35543755
2024 Chimeric PRMT6 protein produced by an endogenous retrovirus promoter regulates cell fate decision in mouse preimplantation embryos†. Biology of reproduction 6 38196172
2024 Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. iScience 6 38303720
2021 Keep it focused: PRMT6 drives the localization of RCC1 to chromosomes to facilitate mitosis, cell proliferation, and tumorigenesis. Molecular cell 4 33740472
2025 PRMT6 promotes colorectal cancer progress via activating MYC signaling. Journal of translational medicine 3 39819457
2025 Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes. PLoS biology 3 40465651
2024 Yifei Sanjie formula alleviates lung cancer progression via regulating PRMT6-YBX1-CDC25A axis. Environmental toxicology 3 38357781
2024 Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity. European journal of medicinal chemistry 3 39276585
2023 Machine Learning for Digital Scoring of PRMT6 in Immunohistochemical Labeled Lung Cancer. Cancers 3 37760550
2018 A coupled fluorescence-based assay for the detection of protein arginine N-methyltransferase 6 (PRMT6) enzymatic activity. Analytical biochemistry 3 29410016
2024 PRMT6-FOXO3A ATTENUATES APOPTOSIS BY UPREGULATING PARKIN EXPRESSION IN INTESTINAL ISCHEMIA-REPERFUSION INJURY. Shock (Augusta, Ga.) 2 38323918
2024 PRMT6 Promotes the Immune Evasion of Gastric Cancer by Upregulating ANXA1. Critical reviews in eukaryotic gene expression 2 38842205
2023 Asymmetric dimethylation of AMPKα1 by PRMT6 contributes to the formation of phase-separated puncta. Biochemical and biophysical research communications 2 37178510
2022 Inhibition of PRMT6 reduces neomycin-induced inner ear hair cell injury through the restraint of FoxG1 arginine methylation. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2 35190853
2025 PRMT6 Inhibits Malignant Progression of Melanoma by Antagonizing Trimethylation of Histone H3K4 to Downregulate ALDH1A1 Levels. Pigment cell & melanoma research 1 40635376
2025 Metformin Impairs Breast Cancer Growth through the Inhibition of PRMT6. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 1 41327885
2024 Enhancement of PRMT6 binding to a novel germline GATA1 mutation associated with congenital anemia. Haematologica 1 38385251
2020 Generation of PRMT6 homozygous knockout human embryonic stem cell lines. Stem cell research 1 33383404
2026 Hypoxia-induced PRMT6 expression promotes temozolomide chemoresistance in glioblastoma via G3BP1. Journal of translational medicine 0 41484630
2026 PRMT6 is required for initiating and amplifying macrophage-induced inflammation in heterotopic ossification by increasing CCL2 expression. Bone research 0 41803087
2025 Assessment of PRMT6-dependent alternative splicing in pluripotent and differentiating NT2/D1 cells. Life science alliance 0 39900436

Missed literature

Know a paper Affinage missed for PRMT6? Flag it for the maintainers and the community.

No submissions yet.